Hemostemix Inc (HEM : TSX-V)
Common Stock
$0.06
CAD
+0.00 (%)
Last updated: 2026-07-06
HEM
Hemostemix Inc
WealthAwesomePerformance
1 Day
+0.00%
1 Week
+0.00%
1 Month
+10.00%
YTD
-38.89%
Key Statistics
Market Cap
$11.27M
52W High
$0.15
52W Low
$0.04
P/E Ratio
-
50 Day MA
$0.06
200 Day MA
$0.08
Beta
0.62
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 7/6/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 1,650 |
| 7/3/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 1,000 |
| 7/2/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 24,000 |
| 6/22/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 5,500 |
| 6/19/2026 | $0.06 | $0.06 | $0.05 | $0.05 | $0.05 | 33,911 |
| 6/18/2026 | $0.06 | $0.06 | $0.05 | $0.05 | $0.05 | 5,000 |
| 6/16/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 15,071 |
| 6/15/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 1,689 |
| 6/11/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 1,001 |
| 6/10/2026 | $0.06 | $0.06 | $0.06 | $0.06 | $0.06 | 5,017 |
Analyst Price Targets
Based on analyst covering HEM
Wall Street analysts forecast HEM stock price to rise 1645.5% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.96
+1645.5% Upside
Current Price
C$0.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HEM's historical volatility
30-Day Vol
105.0%
Annualized
90-Day Vol
96.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.05 | C$0.04 โ C$0.07 |
| 60 trading days | C$0.05 | C$0.03 โ C$0.08 |
| 90 trading days | C$0.05 | C$0.02 โ C$0.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-4.88M
- Profit Margin
- 0.00%
- ROE (TTM)
- 0.00%
- EPS (Diluted)
- -0.02
- Book Value
- -0.03
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About HEM
Articles Featuring HEM.V
Latest articles and analysis covering HEM.V
